Sequential Adjuvant Epirubicin-Based and Docetaxel Chemotherapy for Node-Positive Breast Cancer Patients: The FNCLCC PACS 01 Trial | Zendy

Henri Roché | Zendy; P. Fumoleau | Zendy; M. Spielmann | Zendy; Jean-Luc Ca | Zendy; T. Delozier | Zendy; Daniel Serin | Zendy; Michel Symann | Zendy; Pierre Kerbrat | Zendy; P Soulié | Zendy; Françoise Eichler | Zendy; Patrice Viens | Zendy; Alain Monnier | Zendy; A. Vindevoghel | Zendy; Mario Campone | Zendy; Marie-Josèphe Goudier | Zendy; Jacques Bonneterre | Zendy; JeanMarc Ferrero | Zendy; AnneLaure Martin | Zendy; Jean Genève | Zendy; Bernard Asselain | Zendy

Open Access

Sequential Adjuvant Epirubicin-Based and Docetaxel Chemotherapy for Node-Positive Breast Cancer Patients: The FNCLCC PACS 01 Trial

Author(s) -

Henri Roché,

P. Fumoleau,

M. Spielmann,

Jean-Luc Ca,

T. Delozier,

Daniel Serin,

Michel Symann,

Pierre Kerbrat,

P Soulié,

Françoise Eichler,

Patrice Viens,

Alain Monnier,

A. Vindevoghel,

Mario Campone,

Marie-Josèphe Goudier,

Jacques Bonneterre,

JeanMarc Ferrero,

AnneLaure Martin,

Jean Genève,

Bernard Asselain

Publication year - 2006

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.2006.07.3916

Subject(s) - medicine , epirubicin , docetaxel , febrile neutropenia , breast cancer , oncology , anthracycline , chemotherapy , surgery , neutropenia , cancer

The PACS 01 trial compared six cycles of fluorouracil, epirubicin, and cyclophosphamide (FEC) with a sequential regimen of three cycles of FEC followed by three cycles of docetaxel (FEC-D) as adjuvant treatment for women with node-positive early breast cancer.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research